Tropical Medicine Department.
Internal Medicine department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Eur J Gastroenterol Hepatol. 2022 Mar 1;34(3):332-337. doi: 10.1097/MEG.0000000000002270.
Despite the fact that endoscopy is the gold standard for screening of high-risk varices (HRVs) in patients with compensated cirrhosis, it is invasive, costly and not necessary for all patients. So, noninvasive tests can replace endoscopy. We aimed at evaluating the albumin-bilirubin-platelet (ALBL-PLT) score as a noninvasive test in predicting HRVs in compensated cirrhotic patients versus Baveno VI and extended Baveno VI criteria.
patients with compensated cirrhosis (n = 204) were included. Laboratory parameters, esophagogastroduodenoscopy (EGD) and liver stiffness measurement by transient elastography were done. Classification of patients according to the status of HRVs was done. We compared both groups on the basis of ALBL-PLT score, Baveno VI and extended Baveno VI criteria.
Among the total patients, 96/204 (47%) patients had HRVs. They have higher liver stiffness measurement than those without HRVs (33 ± 13.1 versus 19.3 ± 8.25, CI, -19.94, -7.31, P value <0.001). Also, all HRVs patients have an ALBL-PLT score of more than 3. The area under the receiver operating characteristic curve for the ALBL-PLT score is higher than that for Baveno VI and extended Baveno VI criteria (0.894 versus 0.722 and 0.792, respectively).
ALBL-PLT score of more than three has a good predictive value in predicting HRVs among compensated cirrhotic patients.
尽管内镜检查是筛查代偿性肝硬化患者高危静脉曲张（HRVs）的金标准，但它具有侵袭性、成本高，并非所有患者都需要。因此，可以使用非侵入性检查来替代内镜检查。我们旨在评估白蛋白-胆红素-血小板（ALBL-PLT）评分作为一种非侵入性检查，用于预测代偿性肝硬化患者的 HRVs 与 Baveno VI 和扩展 Baveno VI 标准相比。
纳入了 204 例代偿性肝硬化患者。进行了实验室参数、食管胃十二指肠镜检查（EGD）和瞬时弹性成像的肝硬度测量。根据 HRVs 的情况对患者进行分类。我们根据 ALBL-PLT 评分、Baveno VI 和扩展 Baveno VI 标准对两组进行了比较。
在所有患者中，96/204（47%）例患者存在 HRVs。他们的肝硬度测量值高于无 HRVs 的患者（33 ± 13.1 与 19.3 ± 8.25，CI，-19.94，-7.31，P 值<0.001）。此外，所有 HRVs 患者的 ALBL-PLT 评分均大于 3。ALBL-PLT 评分的受试者工作特征曲线下面积高于 Baveno VI 和扩展 Baveno VI 标准（分别为 0.894 与 0.722 和 0.792）。
ALBL-PLT 评分大于 3 对预测代偿性肝硬化患者的 HRVs 具有良好的预测价值。
